Catalent announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, MO. Two new analytical development laboratories will be added to support the growing demands of assay development for both traditional biologic and advanced biologic modality programs.

The first of two new laboratories will cover approximately 3,500 ft2 and will be completed by the end of the month, with the second, measuring 3,000 ft2, due to be operational in the first quarter of 2023. The expansion is expected to create approximately fifty new scientific jobs at the site by February 2023.

Catalent officials say the additional capacity will increase the capabilities that the company has across its network in both standalone services and integrated development programs. In recent months, Catalent has expanded its CMC large-molecule analytical services at Kansas City to include additional services in excipient and media components support, extractable and leachables testing, droplet digital PCR technologies (ddPCR), and next-generation sequencing (NGS).

“The need for timely analytical support in development, characterization and CGMP testing is critical for innovators across the biologics pipeline, with delays affecting the overall time to get new drugs into the clinic, and ultimately to patients,” said Jeremie Trochu, division head for bioanalytics at Catalent. “Our team at Kansas City serves as a strategic partner for customers of all sizes, and this expansion will allow it to support the increased demand and assay requirements for broad-based and orthogonal analytical CMC services for both traditional biotherapeutics and advanced modalities such as antibody-drug conjugates, cell and gene therapies and mRNA vaccines.”